Aliases:This biomarker is also known as:
- retinal dehydrogenase 2,
- aldehyde dehydrogenase 1 family, member A2,
- retinaldehyde-specific dehydrogenase type 2,
- Aldehyde dehydrogenase family 1 member A2,
- EC 220.127.116.11,
- RALDH 2,
- Retinaldehyde-specific dehydrogenase type 2,
From NCBI Gene: This protein belongs to the aldehyde dehydrogenase family of proteins. The product of this gene is an enzyme that catalyzes the synthesis of retinoic acid (RA) from retinaldehyde. Retinoic acid, the active derivative of vitamin A (retinol), is a hormonal signaling molecule that functions in developing and adult tissues. The studies of a similar mouse gene suggest that this enzyme and the cytochrome CYP26A1, concurrently establish local embryonic retinoic acid levels which facilitate posterior organ development and prevent spina bifida. Four transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, May 2011]
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
ALDH1A2 is a candidate tumor suppressor in prostate cancer.
Significance Analysis of Microarray (SAM) was used to develop a 7-gene classifier. The overall prediction accuracy and sensitivity is 71% and 76%, respectively. The inclusion of the Gleason sum to the seven-gene classifier raised the prediction accuracy and sensitivity to 83% and 76% respectively This prognostic signature is closely associated with biochemical recurrence in patients after radical prostatectomy. The seven genes are: RRAGD, PQBP1, HIST1H2BC, ALDH1A2, TRIM22, RBPMS, HSPB8.
- Expression changes in the stroma of prostate cancer predict subsequent relapse.
- The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer.
- An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account.
- Diagnosis of prostate cancer using differentially expressed genes in stroma.